Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis

Serena Mazzotta, Alessandro Gozzetti, Maria Teresa Pirrotta, Monica Bocchia, Simona Sammassimo, Alessandro Bucalossi, Francesco Lauria

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma. Main toxicity usually consists in somnolence, constipation, peripheral neuropathy and deep vein thrombosis, but, unlike alkylating agents, thalidomide is reported to rarely induce severe hematologic toxicity. The majority of patients developing neutropenia are heavily pretreated with three or more lines of chemotherapy. Here, we report, for the first time, clinical and laboratory data of a 66-year-old female patient with multiple myeloma at diagnosis who, after 4 weeks of thalidomide treatment, developed a grade 4 WHO neutropenia with septicemia. A brief review of the literature and suggestions for possible predictive factors of this toxicity are made.

Original languageEnglish
Pages (from-to)1837-1838
Number of pages2
JournalLeukemia and Lymphoma
Volume46
Issue number12
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Agranulocytosis
Thalidomide
Multiple Myeloma
Neutropenia
Alkylating Agents
Peripheral Nervous System Diseases
Constipation
Venous Thrombosis
Sepsis
Drug Therapy
Therapeutics

Keywords

  • Multiple myeloma
  • Neutropenia
  • Septicemia
  • Thalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Mazzotta, S., Gozzetti, A., Pirrotta, M. T., Bocchia, M., Sammassimo, S., Bucalossi, A., & Lauria, F. (2005). Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis. Leukemia and Lymphoma, 46(12), 1837-1838. https://doi.org/10.1080/10428190500237450

Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis. / Mazzotta, Serena; Gozzetti, Alessandro; Pirrotta, Maria Teresa; Bocchia, Monica; Sammassimo, Simona; Bucalossi, Alessandro; Lauria, Francesco.

In: Leukemia and Lymphoma, Vol. 46, No. 12, 12.2005, p. 1837-1838.

Research output: Contribution to journalArticle

Mazzotta, S, Gozzetti, A, Pirrotta, MT, Bocchia, M, Sammassimo, S, Bucalossi, A & Lauria, F 2005, 'Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis', Leukemia and Lymphoma, vol. 46, no. 12, pp. 1837-1838. https://doi.org/10.1080/10428190500237450
Mazzotta, Serena ; Gozzetti, Alessandro ; Pirrotta, Maria Teresa ; Bocchia, Monica ; Sammassimo, Simona ; Bucalossi, Alessandro ; Lauria, Francesco. / Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis. In: Leukemia and Lymphoma. 2005 ; Vol. 46, No. 12. pp. 1837-1838.
@article{e75b527c17ca4cba9846bb1dad063c2b,
title = "Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis",
abstract = "Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma. Main toxicity usually consists in somnolence, constipation, peripheral neuropathy and deep vein thrombosis, but, unlike alkylating agents, thalidomide is reported to rarely induce severe hematologic toxicity. The majority of patients developing neutropenia are heavily pretreated with three or more lines of chemotherapy. Here, we report, for the first time, clinical and laboratory data of a 66-year-old female patient with multiple myeloma at diagnosis who, after 4 weeks of thalidomide treatment, developed a grade 4 WHO neutropenia with septicemia. A brief review of the literature and suggestions for possible predictive factors of this toxicity are made.",
keywords = "Multiple myeloma, Neutropenia, Septicemia, Thalidomide",
author = "Serena Mazzotta and Alessandro Gozzetti and Pirrotta, {Maria Teresa} and Monica Bocchia and Simona Sammassimo and Alessandro Bucalossi and Francesco Lauria",
year = "2005",
month = "12",
doi = "10.1080/10428190500237450",
language = "English",
volume = "46",
pages = "1837--1838",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis

AU - Mazzotta, Serena

AU - Gozzetti, Alessandro

AU - Pirrotta, Maria Teresa

AU - Bocchia, Monica

AU - Sammassimo, Simona

AU - Bucalossi, Alessandro

AU - Lauria, Francesco

PY - 2005/12

Y1 - 2005/12

N2 - Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma. Main toxicity usually consists in somnolence, constipation, peripheral neuropathy and deep vein thrombosis, but, unlike alkylating agents, thalidomide is reported to rarely induce severe hematologic toxicity. The majority of patients developing neutropenia are heavily pretreated with three or more lines of chemotherapy. Here, we report, for the first time, clinical and laboratory data of a 66-year-old female patient with multiple myeloma at diagnosis who, after 4 weeks of thalidomide treatment, developed a grade 4 WHO neutropenia with septicemia. A brief review of the literature and suggestions for possible predictive factors of this toxicity are made.

AB - Thalidomide represents a recent and innovative therapeutic approach in multiple myeloma. Main toxicity usually consists in somnolence, constipation, peripheral neuropathy and deep vein thrombosis, but, unlike alkylating agents, thalidomide is reported to rarely induce severe hematologic toxicity. The majority of patients developing neutropenia are heavily pretreated with three or more lines of chemotherapy. Here, we report, for the first time, clinical and laboratory data of a 66-year-old female patient with multiple myeloma at diagnosis who, after 4 weeks of thalidomide treatment, developed a grade 4 WHO neutropenia with septicemia. A brief review of the literature and suggestions for possible predictive factors of this toxicity are made.

KW - Multiple myeloma

KW - Neutropenia

KW - Septicemia

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=32144447592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32144447592&partnerID=8YFLogxK

U2 - 10.1080/10428190500237450

DO - 10.1080/10428190500237450

M3 - Article

VL - 46

SP - 1837

EP - 1838

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 12

ER -